Alpha‑Lipoic Acid: No Guideline Recommendation and Insufficient Evidence for Improving Female Fertility

1. Guideline Status and Overall Evidence

• The European Association of Urology (EAU) provides no guideline‑level recommendation for the use of alpha‑lipoic acid (ALA) in female infertility, reflecting the absence of high‑quality data. 1
• The 2025 EAU guidelines on male infertility describe antioxidant therapy evidence as “still conflicting,” and a Cochrane review showed that when high‑risk‑of‑bias studies were excluded, no increase in live‑birth rates was observed. 2
• Across both sexes, a Cochrane review of 48 antioxidant trials reported only 7 studies with clinical‑pregnancy data and 4 with live‑birth data, yielding low‑quality evidence and inadequate safety information. [1][2]

2. Clinical Outcomes Demonstrated (or Not Demonstrated)

• Despite demonstrated antioxidant, anti‑inflammatory, and metabolic effects of ALA in laboratory models, no proven improvement in live‑birth or healthy‑pregnancy outcomes has been documented in women undergoing fertility treatment. [1][2]
• The current evidence base lacks large, well‑designed randomized placebo‑controlled trials with live‑birth as the primary endpoint, preventing ALA from being endorsed as an evidence‑based fertility therapy. [3][4][1][2]

3. Established Lifestyle Interventions with Proven Fertility Benefit

4. Critical Pitfalls to Avoid When Considering ALA

• Do not postpone proven fertility treatments (e.g., IVF, ovulation induction) while trialing ALA, because age‑related fertility decline continues unabated. [5][6]
• Do not rely on antioxidant benefits observed in male infertility to assume similar efficacy in female infertility; the evidence for both is insufficient. [7][3]4

5. Situational Use (Off‑Label, Shared Decision‑Making)

• If a patient with obesity‑related infertility explicitly requests ALA, an off‑label regimen of 800 mg ALA daily plus 2 g myo‑inositol for at least 2 months before ovarian stimulation may be considered, provided it does not delay definitive treatment. 5

6. Research Gaps and Future Directions

• High‑quality, adequately powered RCTs that use live birth as the primary outcome are required before any guideline can endorse ALA for female infertility. [3][4][1][2]

Dieta y Fertilidad: Evidencia Actual

Factores que Afectan la Fertilidad

• El tiempo para lograr embarazo aumenta en mujeres con asma no tratado, sugiriendo que la inflamación sistémica no controlada reduce la fertilidad 8
• La nutrición deficiente conduce a ovulación irregular o amenorrea secundaria, empeorando la fertilidad 8
• Las dietas ricas en carbohidratos refinados, grasas saturadas y bajas en frutas, vegetales y granos enteros se asocian con obesidad y un perfil proinflamatorio que debe evitarse particularmente en mujeres con problemas de fertilidad 9

Suplementación y Fertilidad

• El Colegio Americano de Obstetras y Ginecólogos (ACOG) recomienda combinar vitaminas C y E con tratamiento hormonal de primera línea para manejo del dolor en endometriosis, pero no específicamente para mejorar fertilidad 10
• La Academia Americana de Médicos de Familia establece que el tratamiento médico de endometriosis, incluyendo antioxidantes, no mejora la fertilidad futura 10
• Una revisión Cochrane de 48 estudios encontró que solo 7 reportaron tasas de embarazo clínico y solo 4 reportaron nacidos vivos, con evidencia de baja calidad sugiriendo posible beneficio pero datos insuficientes sobre efectos adversos 11

Recomendaciones Prácticas

• Mantenga un peso saludable, ya que la obesidad y la desnutrición afectan negativamente la fertilidad 8
• Aumente el consumo de frutas, vegetales, granos enteros, pescado y grasas saludables 9
• Reduzca carbohidratos refinados, grasas saturadas, carnes rojas y procesadas 9
• Considere suplementación con vitaminas C y E solo como complemento al tratamiento hormonal en casos de endometriosis con dolor, no como tratamiento primario de fertilidad 10